Espansione Group

Casa
Italia
Argelato
Espansione Group

We Science Onward. Redefining Paradigms in Ophthalmology and Beyond.

Since 1981, Espansione Group has delivered the highest standard in the Ophthalmology and Dermatology industries—pushed on by expert craftsmanship and family-owned values coupled with a global mindset and aspiration. Every day, we invest heavily in researching and developing the Espansione Ecosystem of technologies and solutions to achieve our ambition. Our ambition isn’t limited to that of becomin

g the undisputed thought leader in diagnosing and treating ocular surface conditions. Beyond that, we aim at leveraging our know-how and applying it synergically in other fields beyond ophthalmology. We have already delivered great degrees of innovation to the fields of ophthalmology and dermatology through our patented technology Light Modulation® Low-Level Light Therapy and its seamless integration in the Espansione Ecosystem of solutions. LM® LLLT has set a new medical standard in painlessly and effectively treating the majority of ocular surface conditions, on top of being extremely effective in its dermatology applications.

11/06/2026

A new step forward in understanding ocular surface recovery: new results from a double-masked, RCT reveal how LM™ LLLT (PBM) modulates tear biomarkers involved in tissue repair, neurotrophic support, and inflammation regulation after cataract surgery.

Key outcomes:

✅ Significant increase in GDF-15 in the LLLT group, suggesting activation of intrinsic anti-inflammatory pathways

✅ Increase in PDGF-CC in the LLLT group, supporting reparative pathways involved in tissue reconstruction and epithelial restoration

✅ More pronounced β-NGF increase in LLLT-treated patients, associated with nerve regeneration, epithelial recovery, and tear film stability

✅ Higher clinical improvement rate in the LLLT group vs sham-treated patients: 44.2% vs 4.4%

Together, these results support LM™ LLLT (PBM) as a practical perioperative strategy associated with faster ocular surface recovery, symptom reduction, and tear film stabilization.

Congratulations to the authors — Dr. Timofte Madalina, Dr. Daniel Constantin Branisteanu & team — for their valuable contribution to advancing ocular surface research.

05/06/2026

Managing Demodex Blepharitis and Meibomian Gland Dysfunction (MGD) can be particularly challenging when inflammation, microbial overload and recurrent symptoms coexist.

In this clinical case, a 73-year-old female patient with Demodex Blepharitis and MGD, recurrent marginal keratitis, and excess microbial load (saponification) underwent 4 sessions of Red and Blue LM™ LLLT (PBM) delivered with eye-light®, combined with OPE™ IPL.

Following treatment, the patient showed significant clinical improvement, including marked improvement in meibomian gland viscosity and resolution of saponification, accompanied by visible changes in eyelid margin condition.

📚 This case contributed to the clinical case series that formed the basis of the publication "Intense Pulsed Light Combined with Low Level Blue and Red Light Therapy for Demodex-Associated Blepharitis" by Farrant et al., published in Clinical Ophthalmology (2025).

👉Read Full Article : https://pubmed.ncbi.nlm.nih.gov/40792188/

👏 Special thanks to Dr. Sarah Farrant, OD for sharing this case with us.

28/05/2026

The In-Sight Webinar Series returns with a new program of expert-led sessions exploring the latest advances in ocular surface disease, retinal care and photobiomodulation. ✨

From postoperative dry eye prevention to dry AMD management and ocular microbiome research, this series addresses some of the most relevant challenges in modern ophthalmology through clinically focused, evidence-based discussions. 🚀

This new series will explore topics including:
>Postoperative dry eye prevention after cataract and refractive surgery
>The role of LLLT in surgical patient management
>Combined IPL and Red/Blue Light Therapy for Demodex-associated blepharitis
>Blue light photobiomodulation and the ocular microbiome
>Photobiomodulation in early and intermediate dry AMD

Featuring international experts, randomized clinical studies, real-world protocols, and practical treatment approaches, the series offers valuable educational content for ophthalmologists and eye care professionals looking to stay at the forefront of light-based therapies.

Join the upcoming sessions and discover the latest developments in light-based therapies for ocular surface and retinal care.

Register Now!
👉 https://espansionegroup.it/scientific-community/

15/05/2026

At (Association for Research in Vision and Ophthalmology) 2026, alongside and RetinAI, we presented our vision for an end-to-end workflow proposition for those affected by age-related macular degeneration.

We can't afford to wait for geographic atrophy to take ahold of people's vision.

Thanks to ultra-high-resolution OCT, multimodal imaging and advanced AI-based analytics we'll not only be able to catch disease as early as ever and push the limits of our understanding of it, but also to predict its progression and monitor the impact of therapeutic interventions such as .

The future looks bright for this space, and we can't wait to deliver these innovations at scale for the betterment of all patients.

24/04/2026

The pieces are converging. The evidence is building. And Association for Research in Vision and Ophthalmology (ARVO) is where we push the science further.

Together with EssilorLuxottica, Heidelberg Engineering and RetinAI, we are part of an integrated ecosystem where imaging, AI, and therapeutics converge into a single clinical pathway.

📍 Find us at Booths #9001 & #9009 and let’s talk about what’s next.

Also, don’t miss our scientific program including:
🔬 6+ scientific presentations throughout the week
🗣️ 6 in-booth sessions within Leonardo EssilorLuxottica featuring internationally renowned KOLs
📚 Exhibitor Education Forum | May 5, 11:00 AM (Booth #4111)

25/03/2026

Targeting early structural changes in AMD is becoming an increasingly relevant focus in retina care.

In the LightWave I randomized, sham-controlled trial, a patient with intermediate AMD (AREDS 3) completed two cycles of LM™ LLLT (PBM) with eye-light® over 12 months.

OCT-based follow-up demonstrated a reduction in mean drusen volume, consistent with the statistically significant MDV reduction observed across the PBM-treated cohort — suggesting a potential effect on key structural biomarkers of disease progression.
PBM, a non-invasive intervention, is hypothesized to act through mitochondrial modulation and reduction of oxidative stress.

As clinical evidence continues to expand, ongoing prospective studies will further clarify its role within the AMD therapeutic landscape.

Dive deeper in our scientific bibliography → https://www.espansionegroup.it/bibliography/ -segment

03/03/2026

Managing intermediate AMD requires strategies that support function before progression to advanced stages.

In the LightWave I study, a 73-year-old male patient with intermediate AMD (AREDS 3) underwent two treatment cycles of LM™ LLLT (PBM) delivered with eye-light® over a 12-month period.

At baseline, BCVA was 75 ETDRS letters (20/32). At 12-month follow-up, BCVA improved to 80 ETDRS letters (20/25), reflecting an objective functional enhancement within a structured treatment protocol.

This highlights the potential of PBM to support retinal function, providing measurable anatomical and functional benefits and illustrates the potential role of LM™ LLLT as a practical, non-invasive approach to support retinal function in everyday clinical practice.

👏 Special thanks to Prof. Murat Hasanreisoglu, MD – Koç University, Turkey, for his contribution to this case.

Dive deeper into the scientific evidence → https://espansionegroup.it/bibliography/ -segment

20/02/2026

Real-life impact of PBM in AMD, on AMD Awareness month

In clinical practice, an 85-year-old patient with intermediate dry AMD showed a significant anatomical improvement after just one cycle of PBM (8 sessions), including a marked reduction of a large pigment epithelial detachment (PED).
This case illustrates the potential of LM™ LLLT (PBM) as a practical, non-invasive tool to support retinal structure and function in everyday clinical practice.

👏 Thanks to Dr. Ximena Mira Lorenzo, MD – Centro Oftalmologico Arcos, Mexico City, Mexico.

👉Dive deeper into the scientific evidence: https://espansionegroup.it/bibliography/ -segment

05/02/2026

👁️ February is AMD Awareness Month

Age-Related Macular Degeneration (AMD) is a growing global health challenge, affecting millions of people worldwide—and the numbers continue to rise as populations age.

Early detection makes a difference.
When AMD is identified and treated in its early stages, disease progression can be slowed and vision can be preserved, protecting independence and quality of life.

Together with EssilorLuxottica and Heidelberg Engineering, Espansione Group is committed to advancing awareness, timely diagnosis and innovative solutions—key steps toward better outcomes for patients and healthcare systems alike.

This month, we join the global effort to raise awareness about AMD and the importance of acting early.

22/01/2026

Mucus Fishing Syndrome (MFS) is a chronic inflammatory condition of the ocular surface, characterized by repetitive mechanical removal of mucus that perpetuates inflammation and epithelial damage.

In a recent case series Mancini et al. (2025), prove the effectiveness of LM™ LLLT Photobiomodulation as an adjunctive therapy for the multimodal management of MFS.

In this study, two patients with persistent MFS, refractory to conventional therapy, showed significant improvements in tear film stability, mucus reduction and ocular discomfort after LM™ LLLT.

These preliminary results indicate that LM™ LLLT holds significant potential in the management of complex ocular surface conditions such as MFS, supporting its broader applicability across ocular surface care.

👉 Read the full paper : https://pubmed.ncbi.nlm.nih.gov/41487120/

Indirizzo

Blocco 27 – Via Degli Orefici 152
Argelato
40050

Sito Web

http://espansionegroup.it/

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando Espansione Group pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.